Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HRAS mutation
i
Other names:
HRAS, HRAS1, Harvey rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3265
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
(11)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (NCT05554367)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/13/2024
Initiation :
12/13/2023
Primary completion :
08/26/2026
Completion :
08/26/2026
KRAS • BRAF • NRAS • HRAS • RAS
|
BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12 • HRAS G12C
|
Ibrance (palbociclib) • Mektovi (binimetinib)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (NCT05554328)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/13/2024
Initiation :
04/25/2023
Primary completion :
10/01/2028
Completion :
10/01/2028
KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2
|
KRAS mutation • BRAF mutation • NRAS mutation • NF1 mutation • RAS mutation • HRAS mutation • MAP2K1 mutation
|
Lynparza (olaparib) • Koselugo (selumetinib)
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (19-C-0017) (NCT03745326)
Phase 1/2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
05/16/2019
Primary completion :
12/01/2027
Completion :
12/01/2028
EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS
|
PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients (NCT03190941)
Phase 1/2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
09/21/2017
Primary completion :
06/29/2027
Completion :
06/29/2028
KRAS • ALK • NRAS • HRAS
|
KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors (NCT05585320)
Phase 1/2
Immuneering Corporation
Immuneering Corporation
Recruiting
Phase 1/2
Immuneering Corporation
Recruiting
Last update posted :
05/24/2024
Initiation :
10/31/2022
Primary completion :
06/01/2026
Completion :
06/01/2027
KRAS • HRAS • APC
|
KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation • APC mutation
|
gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • IMM-1-104
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) (NCT06026410)
Phase 1
Kura Oncology, Inc.
Kura Oncology, Inc.
Recruiting
Phase 1
Kura Oncology, Inc.
Recruiting
Last update posted :
04/08/2024
Initiation :
10/18/2023
Primary completion :
01/01/2027
Completion :
04/01/2027
KRAS • NRAS • HRAS
|
KRAS mutation • HRAS mutation • HRAS overexpression
|
Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • KO-2806
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/02/2024
Initiation :
08/14/2014
Primary completion :
08/25/2021
Completion :
01/25/2025
HER-2 • KRAS • BRAF • NRAS • HRAS • EGF
|
KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61
|
Mekinist (trametinib)
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) (NCT04116541)
Phase 2
Centre Leon Berard
Centre Leon Berard
Recruiting
Phase 2
Centre Leon Berard
Recruiting
Last update posted :
03/27/2024
Initiation :
01/28/2020
Primary completion :
02/01/2026
Completion :
11/01/2026
KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK
|
KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer (NCT05111561)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
03/18/2024
Initiation :
08/02/2022
Primary completion :
03/14/2025
Completion :
03/14/2025
HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1
|
BRAF mutation • HER-2 amplification • NF1 mutation • HRAS mutation • BRAF fusion
|
Mektovi (binimetinib) • ZEN-3694
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS (NCT06096974)
Phase 1
Shanghai YingLi Pharmaceutical Co. Ltd.
Shanghai YingLi Pharmaceutical Co. Ltd.
Not yet recruiting
Phase 1
Shanghai YingLi Pharmaceutical Co. Ltd.
Not yet recruiting
Last update posted :
10/24/2023
Initiation :
10/01/2023
Primary completion :
04/01/2025
Completion :
04/01/2026
PD-L1 • KRAS • NRAS • HRAS
|
KRAS mutation • NRAS mutation • HRAS mutation
|
YL-17231
Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) (NCT03714958)
Phase 1
Centre Leon Berard
Centre Leon Berard
Completed
Phase 1
Centre Leon Berard
Completed
Last update posted :
09/13/2023
Initiation :
12/20/2018
Primary completion :
09/12/2023
Completion :
09/12/2023
KRAS • TP53 • NRAS • HRAS
|
TP53 mutation • BRAF mutation • TP53 wild-type • HRAS mutation
|
Mekinist (trametinib) • siremadlin (HDM201)
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer (NCT04146298)
Phase 1/2
Changhai Hospital
Changhai Hospital
Recruiting
Phase 1/2
Changhai Hospital
Recruiting
Last update posted :
09/01/2023
Initiation :
10/21/2021
Primary completion :
12/01/2024
Completion :
03/01/2025
KRAS • NRAS • HRAS
|
KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies (NCT04566393)
Phase N/A
xCures
xCures
Available
Phase N/A
xCures
Available
Last update posted :
08/21/2023
BRAF • NRAS • HRAS • MAPK1
|
BRAF mutation • ER mutation • HRAS mutation
|
ulixertinib (BVD-523)
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome (NCT04487106)
Phase 2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Completed
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
03/07/2023
Initiation :
07/21/2020
Primary completion :
02/09/2023
Completion :
02/09/2023
KRAS • BRAF • NRAS • KIT • HRAS • NF1 • PTPN11
|
KRAS mutation • BRAF mutation • NRAS mutation • KIT mutation • NF1 mutation • HRAS mutation • CBL mutation
|
Venclexta (venetoclax) • Mekinist (trametinib) • azacitidine
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (SEQ-HN) (NCT03719690)
Phase 2
Kura Oncology, Inc.
Kura Oncology, Inc.
Active, not recruiting
Phase 2
Kura Oncology, Inc.
Active, not recruiting
Last update posted :
11/09/2022
Initiation :
11/05/2018
Primary completion :
05/30/2023
Completion :
05/31/2023
HRAS
|
RAS wild-type • HRAS mutation • HRAS wild-type
|
Zarnestra (tipifarnib)
Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma (NCT02535650)
Phase 2
Samsung Medical Center
Samsung Medical Center
Active, not recruiting
Phase 2
Samsung Medical Center
Active, not recruiting
Last update posted :
03/08/2022
Initiation :
11/12/2015
Primary completion :
03/01/2022
Completion :
06/01/2022
STK11 • HRAS
|
STK11 mutation • HRAS mutation
|
Zarnestra (tipifarnib)
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE) (NCT03244956)
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy, Cancer Campus, Grand Paris
Active, not recruiting
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Active, not recruiting
Last update posted :
09/28/2021
Initiation :
12/27/2017
Primary completion :
11/18/2021
Completion :
12/01/2022
KRAS • NRAS • HRAS
|
BRAF V600E • BRAF V600 • HRAS mutation • BRAF K601E • BRAF K601
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations (KO-TIP-001) (NCT02383927)
Phase 2
Kura Oncology, Inc.
Kura Oncology, Inc.
Completed
Phase 2
Kura Oncology, Inc.
Completed
Last update posted :
05/14/2021
Initiation :
03/01/2015
Primary completion :
11/30/2020
Completion :
11/30/2020
HRAS
|
HRAS mutation
|
Zarnestra (tipifarnib)
A Study of ASN007 in Patients With Advanced Solid Tumors (NCT03415126)
Phase 1
Asana BioSciences
Asana BioSciences
Completed
Phase 1
Asana BioSciences
Completed
Last update posted :
07/09/2020
Initiation :
01/19/2018
Primary completion :
06/30/2020
Completion :
06/30/2020
KRAS • HRAS
|
KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation
|
ERAS-007
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors (NCT03266159)
Phase 2
GlaxoSmithKline
GlaxoSmithKline
Withdrawn
Phase 2
GlaxoSmithKline
Withdrawn
Last update posted :
12/08/2017
Initiation :
11/27/2017
Primary completion :
08/19/2020
Completion :
08/19/2020
KRAS • NRAS • HRAS • NF1 • CCL2
|
KRAS mutation • NRAS mutation • NF1 mutation • HRAS mutation
|
Mekinist (trametinib) • molibresib (GSK525762)
Biomarkers in Patients With Head and Neck Cancer (NCT01466257)
Phase N/A
ECOG-ACRIN Cancer Research Group
ECOG-ACRIN Cancer Research Group
Completed
Phase N/A
ECOG-ACRIN Cancer Research Group
Completed
Last update posted :
05/19/2017
Initiation :
11/21/2011
Primary completion :
01/01/2012
Completion :
01/01/2012
PIK3CA • HRAS
|
PIK3CA mutation • HRAS mutation
|
Erbitux (cetuximab) • cisplatin
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer (NCT02573220)
Phase 1
University of Chicago
University of Chicago
Withdrawn
Phase 1
University of Chicago
Withdrawn
Last update posted :
12/09/2016
Initiation :
06/01/2015
Primary completion :
08/01/2016
Completion :
08/01/2016
KRAS • NRAS • HRAS • UGT1A1
|
KRAS mutation • RAS wild-type • HRAS mutation • UGT1A1*28 • UGT1A1*1*1
|
Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login